Albuquerque, NM, April 17, 2025 – Indica Labs, the leading provider of AI-powered digital pathology solutions, announces today the expansion of their macrodissection suite with the launch of CRC Macrodissect AI. This expanded portfolio of AI powered tools by Indica Labs will facilitate a macrodissection workflow that minimizes human error and improves efficiency across multiple disease sites. Utilizing the integrative power of artificial intelligence and digital pathology, CRC Macrodissect AI will advance the field of molecular pathology and offer unparalleled insight into colorectal carcinoma.  

Tumor tissue quality and macrodissection accuracy are essential for downstream molecular analysis; however, the current gold standard for tissue selection and dissection is subjective, error-prone, labor-intensive, and lacks auditability.  

Indica Labs’ HALO Macrodissection Solutions address these challenges by quantifying tumor content across whole slide images subsequently generating real-time tumor content calculations that update cumulatively with each region of interest (ROI) selected. Tumor cell density heatmaps display areas of tumor enrichment, guiding the pathologist in the annotation process. This method standardizes tumor content assessment, minimizes the tedious nature of manual cell counts, and streamlines the macrodissection annotation process in cases of colorectal carcinoma.  

CRC Macrodissect AI integrates seamlessly into HALO AP®, the enterprise digital pathology platform from Indica Labs, and can be combined with the Tissector line of robotic macrodissectors from our partner, Xyall, for a fully automated and audited workflow. This integration enhances the accuracy of the macrodissection process and increases throughput and operational efficiency, freeing pathologists to focus on more complex tasks.  

“We’re excited to announce the expansion of our macrodissection portfolio,” said Steven Hashagen, CEO of Indica Labs. “With products now available for both lung and colorectal cancer, this will continue to advance the field of molecular pathology to make genetic testing more reliable.” 

CRC Macrodissect AI harnesses the power of AI to objectively score every cell across a whole slide image, highlighting cancerous tissue and ensuring the concentration and purity of a sample is adequate for downstream molecular analysis. Standardizing the tumor enrichment process improves overall efficiency and reliability while improving confidence in molecular test results.  

Beyond the quantification of tumor cells, the adoption of artificial intelligence in the macrodissection workflow creates an auditable process that is invaluable. The current laboratory procedure includes disposal of glass slides immediately following manual dissection, leaving the process untraceable and fully reliant on the judgement and skills of the laboratory staff. Digitizing this process allows the pathologist to trace and document the entire macrodissection workflow for quality assurance while reducing the need for expensive repeat molecular testing. 

Clinical validation was conducted on 280 primary and metastatic whole slide images from an external site that were previously unseen to the algorithm. Comparing five pathologists’ tumor content estimations with and without assistance from CRC Macrodissect AI revealed significant improvements in agreement and consistency when aided by the algorithm. Without AI assistance, the consistency between pathologists (ICC) was relatively low at 0.50. The agreement measure (Fleiss’ kappa) when specimens were binarized using a 20% tumor content cut-off, the minimum requirement for most molecular tests, was also low at 0.36. With AI assistance, the ICC score increased to 0.83, and the Fleiss’ kappa statistic rose to 0.66, indicating a substantial and significant improvement in consistency of tumor content estimation across pathologists. 

CRC Macrodissect AI is available in the HALO AP® platform, trusted for its robust suite of tools for annotation, collaboration, and image analysis. HALO AP® offers seamless interoperability and compatibility with a wide range of scanners and file types, clinical data systems, and AI and image analysis tools, ensuring flexibility and ease of use in diverse laboratory environments.   

For more information about CRC Macrodissect AI, HALO Macrodissection Solutions, and how these algorithms can enhance efficiency and accuracy in your laboratory, contact info@indicalab.com. 

CRC Macrodissect AI is not a medical device in the EU/UK and is not intended to be used for diagnostic purposes. CRC Macrodissect AI is accessed via the HALO AP® enterprise digital pathology platform. CRC Macrodissect AI is For Research Use Only in the USA and is not FDA cleared for clinical diagnostic use.  

HALO AP® is CE-IVDR marked for in-vitro diagnostic use in Europe, the UK, and Switzerland. HALO AP® is For Research Use Only in the USA and is not FDA cleared for clinical diagnostic use. In addition, HALO AP® provides built-in compliance with FDA 21 CFR Part 11, HIPAA, and GDPR.  

About Indica Labs: Indica Labs is the global leader in AI-powered digital pathology software and services. Our flagship HALO® and HALO AI platform revolutionizes quantitative evaluation of whole slide images. HALO Link provides collaborative image management while HALO AP® and HALO AP Dx deliver enterprise digital pathology for primary diagnosis with regulatory clearances in multiple markets. Through a commitment to open pathology, performance, scalability, and ease-of-use, we help pharma companies, diagnostic labs, hospitals, research organizations, and Indica’s own Cloud and Pharma Services make discoveries and diagnoses that transform patient care and scientific discovery.    

Media Contact:  

Eric Runde 

erunde@indicalab.com